Vertex Pharmaceuticals will acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2019-06-06 18:43:282019-06-07 12:56:20Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals